Delays in obtaining pricing and reimbursement (P&R) have been identified as key hurdles holding back the pharmaceutical industry, according to market analysis. This trend is highlighted through responses to a survey taken from GlobalData’s State of the Biopharmaceutical Industry report, which reveals that industry professionals rate the impact of P&R processes among the top five leading factors currently impacting the sector. GlobalData is the parent company of Pharmaceutical Technology. In the survey, ...

The White House launched its drug-pricing website, dubbed TrumpRx, with obesity and infertility treatments among the first crop to appear with discounts on the government-run platform. https://t.co/a01BfjdH4o ...

🚨UPDATE: WHITE HOUSE LAUNCHES TRUMPRX DRUG PRICING PORTALAccording to the WSJ, TrumpRx drug-pricing portal, launched Thursday evening, offering cash-pay discounts on 43 brand-name drugs from five manufacturers: AstraZeneca, Eli Lilly, EMD Serono, Novo Nordisk, and Pfizer.Drugs from 11 additional manufacturers will be added in coming months.BSCN (@BSCNews):🚨NEW: TRUMP ADMINISTRATION TO LAUNCH TRUMPRX DRUG PRICING PORTAL TONIGHT?TrumpRx is expected to launch Tonight, according @Axios.The direct-to-consumer pl ...

The White House on Thursday launched its drug-pricing website, dubbed TrumpRx, the culmination of efforts by the administration to bring down pharmaceutical costs for some consumers. ...

🚨NEW: TRUMP ADMINISTRATION TO LAUNCH TRUMPRX DRUG PRICING PORTAL TONIGHT?TrumpRx is expected to launch Tonight, according @Axios.The direct-to-consumer platform will connect cash-paying patients with manufacturer drug programs.Sixteen drugmakers have signed agreements, with advertised prices including GLP-1s Zepbound and Wegovy at $149/month, Repatha at $239/month, and Januvia at $100. ...

Core Viewpoint - Cigna Corp's Express Scripts has reached a settlement with the U.S. Federal Trade Commission regarding claims that its insulin pricing practices violated antitrust and consumer protection laws, and has agreed to implement changes aimed at lowering insulin costs for consumers [1] Group 1: Settlement Details - The settlement addresses allegations of antitrust violations related to insulin pricing practices [1] - Changes agreed upon by Express Scripts are intended to reduce insulin costs for consumers [1] Group 2: Regulatory Context - The U.S. Federal Trade Commission's involvement highlights ongoing scrutiny of pharmaceutical pricing practices [1] - This settlement may set a precedent for future regulatory actions against similar pricing practices in the healthcare industry [1]

Drugmakers are doing something unusual this year: slashing prices for several widely used medicines. 🔗 https://t.co/lRgRN5CAJx https://t.co/LOSg7h8fIY ...

At the start of every year, drugmakers raise prices for their medicines. But this year, they cut the prices of some popular treatments. https://t.co/6LkbVsqRHB ...

The US plans to slash the price it pays for Botox and diabetes drug Trulicity, the latest medicines to be targeted under legislation that’s expected to save the government more than $200 billion over a decade https://t.co/uRG8ldE5eG ...

Core Viewpoint - Johnson & Johnson has provided a sales and profit guidance for the current year that surpasses Wall Street expectations, despite anticipating a significant financial impact from a recent drug pricing agreement with the U.S. government [1][3]. Group 1: Financial Guidance - The company expects current-year sales to be between $100 billion and $101 billion, exceeding consensus estimates of $98.88 billion [4]. - Full-year earnings are projected to be between $11.43 and $11.63 per share, compared to expectations of $11.45 [4]. Group 2: Recent Developments - Johnson & Johnson agreed to lower drug prices for U.S. consumers in exchange for exemptions from broad tariffs, aligning with actions taken by other major pharmaceutical companies [2]. - This initiative is part of broader efforts by the U.S. government to reduce drug costs, particularly in the lead-up to the midterm elections [2]. Group 3: Financial Performance - For the fourth quarter, the company reported revenue of $24.56 billion, reflecting a year-over-year increase of 9.1% and surpassing projections of $24.15 billion [4]. - The strong performance was driven by high demand for medical technology products and a 27% increase in sales of the Darzalex blood cancer treatment [4]. Group 4: Earnings Performance - Adjusted earnings per share reached $2.46, exceeding analyst estimates of $2.04, despite a decline in sales of the psoriasis drug Stelara due to rising biosimilar competition [5].